Drug Profile
NS3/4A inhibitor + NS5A inhibitor - Ginkgo Pharma
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Ginkgo Pharma
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Hepatitis-C in China
- 20 Jul 2016 Preclinical trials in Hepatitis C in China (unspecified route)